Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
Meghan S. Vermillion(Lovelace Respiratory Research Institute), Danielle Porter(Gilead Sciences (United States)), Hammad Irshad(Lovelace Medical Center), Jesse Yang(Université Bourgogne Franche-Comté), Davin Rautiola(Université Bourgogne Franche-Comté), Bill J. Smith(Gilead Sciences (United States)), Jim Hartke(Université Bourgogne Franche-Comté), Raju Subramanian(Gilead Sciences (United States)), Darius Babusis(Gilead Sciences (United States)), Roy Bannister(Gilead Sciences (United States)), Bin Ma(Tongji University), Tomáš Cihlář(Gilead Sciences (United States)), Cynthia Kim(Gilead Sciences (United States)), Adrian Tomkinson(Gilead Sciences (United States)), Scott Ellis(Université Bourgogne Franche-Comté), Nani Kadrichu(Inspire), William A. Lee(Université Bourgogne Franche-Comté), John P. Bilello(Global Vaccines (United States)), Jared Pitts(Gilead Sciences (United States)), Dustin Seigel(Université Bourgogne Franche-Comté), Eisuke Murakami(Gilead Sciences (United States)), Congrong Niu(Gilead Sciences (United States)), Xiaofeng Zhao(Gilead Sciences (United States)), Richard L. Mackman(Gilead Sciences (United States)), Andrew P. Gigliotti(Lovelace Medical Center), Philip J. Kuehl
Cited by 42
Related Papers
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
|Cell Reports|2020|541
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325